Abstract CHORUS (NCT04905316) was an open-label, non-randomized, single-arm phase I/II trial of the anti-IL-1beta monoclonal antibody canakinumab given with concurrent chemoradiotherapy and continued with anti-PD-L1 durvalumab consolidation in unresectable stage III non-small cell lung cancer. The primary endpoint was 24-month progression-free survival (PFS) from radiotherapy initiation; secondary endpoints included overall survival, objective response rate, and safety.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Boris
Contact Boris, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack